Esperion's NEXLETOL Receives National Pricing Approval in Japan, Launches and Receives $90 Million Payment

Esperion's partner Otsuka has received approval and launched NEXLETOL in Japan for treating hypercholesterolemia and familial hypercholesterolemia. The launch is a significant commercial milestone, marking the third largest global market for cardiovascular prevention. Otsuka will pay Esperion a total of $90 million, strengthening Esperion's financial position. The approval and launch highlight the strategic value of the partnership between the two companies.